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Abstract
Background: The Fanconi anemia (FA) pathway is a multigene DNA damage response network
implicated in the repair of DNA lesions that arise during replication or after exogenous DNA
damage. The FA pathway displays synthetic lethal relationship with certain DNA repair genes such
as ATM (Ataxia Telangectasia Mutated) that are frequently mutated in tumors. Thus, inhibition of
FANCD2 monoubiquitylation (FANCD2-Ub), a key step in the FA pathway, might target tumor
cells defective in ATM through synthetic lethal interaction. Curcumin was previously identified as
a weak inhibitor of FANCD2-Ub. The aim of this study is to identify derivatives of curcumin with
better activity and specificity.
Results: Using a replication-free assay in Xenopus extracts, we screened monoketone analogs of
curcumin for inhibition of FANCD2-Ub and identified analog EF24 as a strong inhibitor. Mechanistic
studies suggest that EF24 targets the FA pathway through inhibition of the NF-kB pathway kinase
IKK. In HeLa cells, nanomolar concentrations of EF24 inhibited hydroxyurea (HU)-induced
FANCD2-Ub and foci in a cell-cycle independent manner. Survival assays revealed that EF24
specifically sensitizes FA-competent cells to the DNA crosslinking agent mitomycin C (MMC). In
addition, in contrast with curcumin, ATM-deficient cells are twofold more sensitive to EF24 than
matched wild-type cells, consistent with a synthetic lethal effect between FA pathway inhibition and
ATM deficiency. An independent screen identified 4H-TTD, a compound structurally related to
EF24 that displays similar activity in egg extracts and in cells.
Conclusions: These results suggest that monoketone analogs of curcumin are potent inhibitors
of the FA pathway and constitute a promising new class of targeted anticancer compounds.
Background
Fanconi anemia (FA) is a multigene genetic disease char-
acterized by developmental defects, early bone marrow
failure and genomic instability leading to a high incidence
of cancers [1]. At the molecular level, the FA pathway is a
highly integrated DNA damage response network of pro-
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particularly DNA interstrand crosslinks [2,3]. The path-
way is composed of a core complex of at least 10 proteins
(including FANCA, B, C, E, F, G, L, M, FAAP24 and
FAAP100) that function as an E3 ubiquitin ligase for the
monoubiquitylation and activation of FANCD2 and
FANCI [3]. Downstream proteins such as FANCD1/
BRCA2, FANCJ/BRIP1 and FANCN/PALB2 have been
linked to elevated risk of breast and ovarian cancers [4].
However, although the FA pathway is well-defined bio-
chemically, its precise roles in the DNA damage response
remain obscure.
The FA pathway is a potential target in anticancer therapy
either through chemosensitization of tumor cells to DNA
crosslinking agents such as melphalan and cisplatin [5,6]
or by exploiting synthetic lethal interactions. Two genes
have a synthetic lethal relationship if mutants for either
gene are viable but the double mutation is lethal [7]. Tar-
geting this particular type of genetic interaction in tumors
is currently the subject of intense development due to the
promising results of clinical trials using PARP inhibitors
in BRCA1/2-deficient breast tumors [8,9]. High-through-
put screens to identify genes displaying synthetic lethal
interaction with genes frequently impaired in tumors are
demonstrating the potential for discovering functional
dependencies created by oncogenic mutations that may
enable therapeutic intervention for cancers with "undrug-
gable" genetic alterations such as RAS [10,11]. With
regard to FA, D'Andrea and coworkers identified a set of
DNA damage response genes required for the survival of
FA-deficient cells including ATM (Ataxia Telangectasia
Mutated)[12]. ATM is a major kinase involved in the sens-
ing and repair of DNA double-strand breaks by homolo-
gous recombination [13]. Germline mutations in this
gene cause the Ataxia Telangectasia cancer susceptibility
syndrome [14], and ATM deficiencies (mutations or lack
of expression) are also frequent in sporadic hematological
malignancies such as chronic lymphocytic leukemia [15]
and mantle cell lymphoma [16]. Because deficiency in the
FA pathway is not lethal [2], specific inhibitors are
expected to display low toxicity toward normal cells but
kill tumor cells deficient in ATM or other genes with syn-
thetic lethal relationships to the FA pathway.
A cell-based screen for inhibitors of FANCD2 monoubiq-
uitylation (FANCD2-Ub) recently identified curcumin
[5], a phytochemical with anticancer properties that have
been linked to a variety of mechanisms including apopto-
sis through the NFκB pathway [17]. Efforts to develop cur-
cumin analogs with improved solubility, stability and
activity have led to the generation of a series of monoke-
tone derivatives including EF24, a strong candidate for
further drug development in cancer therapy [18-22]. We
evaluated these curcumin analogs in a cell-free assay that
uses Xenopus egg extracts to uncouple FANCD2-Ub from
ongoing replication [6,23-26]. The most active com-
pounds were subsequently tested in mammalian cells for
FA pathway inhibition and synthetic lethal interactions.
Results
Inhibition of xFANCD2-Ub by monoketone analogs of 
curcumin in Xenopus extracts
A series of monoketone analogs of curcumin [18] was
evaluated in Xenopus egg extracts where DNA substrate-
induced xFANCD2-Ub is used as a readout of FA pathway
performance [6,23,24]. Phosphorylation of MRE11
(MRE11-P), a member of the MRN DNA damage repair
pathway [27,28] was monitored to assess the cross-specif-
icity of the compounds. For each compound, IC50 values
were determined from serial dilution experiments and
densitometry analysis of immunoblots. Five analogs were
at least 10 fold more active than curcumin both for inhi-
bition of xFANCD2-Ub and xMRE11-P (Fig. 1A). Struc-
ture-activity relationship (SAR) analysis (Fig. 1B)
suggested that a pyridine terminal aromatic ring and a
nitrogen substitution in the central ring (analogs EF24,
EF31, AS153-4, AS153-5) were important for activity.
Accessibility of the lone electron pair on the nitrogen
atom within the ring is crucial since movement of the
basic nitrogen outside the ring (0810-117) or masking by
a butoxycarbonyl (Boc) group (0616-104) decreases com-
pound activity to non-detectable levels in Xenopus extracts.
Replacement of the central ring nitrogen with sulfur while
retaining the pyridine rings (0821-120A) drops the activ-
ity only slightly, whereas the same compound with an
oxygen in the central ring was only weakly active (0822-
3). None of the other combinations displayed a detectable
activity in Xenopus extracts. Phosphorylation of other pro-
teins involved in DNA damage response (RPA32 [29] and
H2AX, Fig. 1C) was not inhibited by the curcumin ana-
logs.
Mechanism of xFANCD2-Ub inhibition by EF24
To explore potential mechanisms by which curcumin ana-
logs inhibit the FA pathway, we evaluated the integrity of
the FA core complex in Xenopus extracts containing EF24,
one of the most active analogs. In human cells,
hFANCD2-Ub is reduced when FA core complex proteins
are defective or absent. However we found that the integ-
rity of the core complex was unchanged in the presence or
absence of EF24 (Additional File 1 - Fig. S1). Next, we
found that EF24 did not detectably interfere with the
recruitment of the core complex to DNA, a crucial step for
xFANCD2 activation in Xenopus extracts (data not shown,
[24]).
The proteasome is required for the monoubiquitylation of
xFANCD2 in cells [30]. As curcumin has proteasome
inhibiton activities [31], we tested whether EF24 inhibitsPage 2 of 13
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ities (caspase-like and chymotrypsin-like) along with
xFANCD2-Ub status were monitored in activated Xenopus
extracts treated with various compounds (Fig. 2A).
MG132 (a potent and specific proteasome inhibitor) and
curcumin efficiently inhibited both proteasome activities
but had only a weak activity on xFANCD2-Ub. By con-
trast, EF24 was 20-fold less active than curcumin for pro-
teasome inhibition while displaying a strong activity
against xFANCD2-Ub. Finally, the 0810-117 analog had
weak inhibitory activities against both the proteasome
and xFANCD2-Ub. To confirm the result obtained with
EF24, we further tested EF31 and AS153-4, two close ana-
logs that display a strong activity against xFANCD2-Ub
(See Fig. 1A). Similar to EF24, both were 20-fold less
active than curcumin for proteasome inhibition activity
(Fig. 2B). Taken together, these results demonstrate that in
Xenopus extracts EF24 and other monoketone analogs of
curcumin do not inhibit the FA pathway by inhibiting the
proteasome.
IκB kinase (IKK), a critical mediator of the NFκB pathway
and the cellular response to stress, has recently been iden-
tified as an important target of EF24 for its apoptosis-
mediated toxicity in cancer cells [32]. Interestingly, IKK
has been suggested to play a role in the activation of the
FA pathway [33]. We tested whether EF24 inhibits IKK
activity in Xenopus extracts by monitoring the accumula-
tion of the IKK target, IκB-α (Fig. 3A). Because IκB-α phos-
phorylation by IKK leads to its degradation by the
ubiquitin-proteasome pathway, inhibition of IKK results
in the accumulation of IκB-α. For this experiment, we
used extracts prepared without cycloheximide to allow for
de novo translation of IκB-α. We found that the level of
IκB-α increased upon treatment of extracts with EF24,
demonstrating that EF24 inhibits IKK in Xenopus extracts.
Next, we reasoned that if EF24 inhibits xFANCD2-Ub
through inhibition of IKK, a specific IKK inhibitor should
inhibit xFANCD2-Ub. After treatment of Xenopus extracts
with increasing concentrations of BMS-345541, a specific
and potent IKK inhibitor [34], xFANCD2-Ub was inhib-
ited in a dose-dependent manner (Fig. 3B). Similar to
EF24 treatment, MRE11 phosphorylation was inhibited
along with xFANCD2-Ub. EF24 was 10-15 times more
active than BMS-345541 for xFANCD2-Ub inhibition
(EC50: 60 μM vs. 970 μM) and IκB-α stabilization (EC50:
30 μM vs. 280 μM). Interestingly, EF24 and BMS-345541
concentrations required for xFANCD2-Ub inhibition were
Curcumin analogs efficiently inhibit xFANCD2 monoubiquitylation in Xenopus extractsFigure 1
Curcumin analogs efficiently inhibit xFANCD2 monoubiquitylation in Xenopus extracts. A) Inhibition of 
xFANCD2-Ub and xMRE11 phosphorylation by curcumin anlogs. IC50 values were determined using immunoblots of plasmid-
activated extracts treated with a range of concentrations for each compound (0, 10, 25, 60, 150, 400, 1000, 3000 μM). A rep-
resentative experiment is shown (out of 3 repeats). B) Structure of curcumin and monoketone analogs. C) Curcumin analogs 
do not affect RPA32 and H2AX phosphorylation. Activated extracts were treated with 1 mM each compound and phosphoryla-
tion of RPA32 and H2AX monitored by immunoblot.Page 3 of 13
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EC50: 60 μM vs. 30 μM; BMS-345541 EC50: 970 μM vs.
280 μM, Fig. 3A and 3B), suggesting that the kinase activ-
ity of IKK is not crucial for xFANCD2-Ub in Xenopus
extracts. To investigate this idea further, we tested whether
EF24 inhibition of xFANCD2-Ub is dependent on phos-
phorylation (Fig. 3C). Treatment of extracts with tautomy-
cin, a PP1/PP2A phosphatase inhibitor, resulted in the
accumulation of xMRE11-P even in the presence of EF24
but had no detectable effect on xFANCD2-Ub. Treatment
with caffeine, a PIKK kinase inhibitor, significantly inhib-
ited xMRE11-P (compare lane 12 and lanes 15, 18) but
co-treatment with EF24 did not alter the pattern of
xFANCD2-Ub inhibition (compare lanes 12-14 and 15-
17, 18-20). Since caffeine is not a general kinase inhibitor,
we also used shrimp alkaline phosphatase (SAP) to
dephosphorylate proteins non-specifically in extracts.
Treatment with 0.1 u/μl SAP significantly reduced
xMRE11-P levels (compare lanes 12 and 24) but did not
affect EF24-dependent inhibition of xFANCD2-Ub (com-
pare lanes 12-14 and 24-26). Taken together, these results
suggest that EF24 might inhibit the FA pathway by target-
ing IKK through a mechanism that does not involve inhi-
bition of IKK kinase activity.
EF24 inhibits hFANCD2-Ub and hFANCD2 foci in HeLa 
cells
We next determined whether EF24 could inhibit
hFANCD2-Ub in human cells. Curcumin was tested in
parallel to assess whether activity difference observed in
extracts are mirrored in cells. HeLa cells were co-treated
with increasing concentrations of compounds and
hydroxyurea (HU), a standard method to stimulate
hFANCD2-Ub (Fig. 4A, lanes 1-2, 7-8, [30]). Immunoblot
and densitometry analysis revealed that EF24 is 40-fold
more active than curcumin for hFANCD2-Ub inhibition
(IC50: 0.39 μM vs. 15 μM), in line with the stronger activ-
ity of EF24 observed in extracts.
As the activity of the FA pathway is cell cycle dependent,
we monitored the effect of HU and EF24 on the cell cycle
by FACS analysis. We found no significant change in the
cell cycle profile of cells treated with HU in combination
with EF24 compared to that of untreated cells (Additional
File 1 - Fig. S2), suggesting that EF24 does not inhibit
hFANCD2-Ub through perturbation of the cell cycle.
To confirm inhibition of the FA pathway using another
readout, we monitored the effect of EF24 on HU-induced
hFANCD2 foci in HeLa cells (Fig. 4B) [29]. IC50 values for
inhibition of foci formation were in the same range as
IC50 values for hFANCD2-Ub inhibition, an expected
result since hFANCD2-Ub but not the unmodified
hFANCD2 is competent to form foci [35].
EF24 sensitizes FA-competent cells to mitomycin C (MMC)
We tested whether EF24 is a specific inhibitor of the FA
pathway by comparing its effect on a FANCA-deficient cell
line (HSC72OT) and its complemented, wild-type-like
counterpart (HSC72OT+A) [36] in the presence of the
DNA crosslinking agent MMC. If EF24 specifically targets
the FA pathway, it should sensitize FA-competent cells to
MMC but not FA-deficient cells.
Proteasome inhibition activity of EF24 and related curcumin analogs in Xenopus extractsFigure 2
Proteasome inhibition activity of EF24 and related curcumin analogs in Xenopus extracts. A) Inhibition of caspase- 
and chymotrypsin-like proteasome activities and xFANCD2-Ub by MG132, curcumin and curcumin analogs. Proteasome activ-
ities and xFANCD2-Ub were monitored using fluorogenic probes and immunoblotting, respectively. IC50 values were deter-
mined for each compound using a range of concentrations and represented in histogram graphs. For MG132, numbers above 
caspase-like and chymotrypsin-like histograms indicate the actual IC50 values. A representative experiment is shown (out of 3 
repeats). B) Inhibition of proteasome activities by EF31 and AS153-4 compared to curcumin.Page 4 of 13
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MMC compared to HSC72OT (Fig. 5A, compare solid line
curves in left and right panels). 100 nM EF24, a concentra-
tion that did not affect survival in either cell line (Fig. 5B)
slightly reduced the survival of MMC-treated HSC72OT
cells (Fig. 5A, left panel). By contrast, the same treatment
induced a significant decrease of cell survival in
HSC72OT+A cells (Fig. 5A, right panel), suggesting that
EF24 sensitized HSC72OT+A cells to MMC by inhibiting
the FA pathway.
Sensitivity of ATM-deficient cells to EF24 suggests a 
synthetic lethal effect
Kennedy et al [12] identified ATM in a screen for genes
that display a synthetic lethal relationship with the FA
pathway, suggesting that inhibition of the FA pathway
could selectively kill ATM-deficient cells. To test this pos-
sibility, we compared the effects of curcumin and EF24 in
an ATM KO mouse kidney cell line (309ATM KO) and its
isogenic, wild type counterpart (334ATM WT). As expected
from ATM deficiency, 309ATM KO cells were more sensitive
to ionizing irradiation than 334ATM WT (Additional File 1 -
Fig. S3). We next treated these cell lines with various con-
centrations of EF24 and measured their survival after 72
hrs. Fig. 6A shows that 309ATM KO cells were twofold more
sensitive to EF24 than 334ATM WT cells (2.6 vs. 5.8 μM). In
contrast, 309ATM KO cells were slightly more resistant than
334ATM WT to curcumin (23 vs. 17 μM, Fig. 6B), possibly
due to the pleiotropic effects of curcumin masking the
weak FA pathway inhibition activity. To rule out a general
chemical sensitivity of the ATM KO cell line, we also tested
the casein kinase II inhibitor DRB, a compound with no
effect on the FA pathway in Xenopus extracts (data not
shown). As expected, DRB displayed similar toxicity in
both cell lines (Fig. 6C).
These results suggest that the toxicity of EF24 observed in
ATM-deficient cells may be caused by a synthetic lethal
EF24 does not inhibit xFANCD2-Ub through modulation of a phosphorylation event, but IKK inhibition might play a roleFigure 3
EF24 does not inhibit xFANCD2-Ub through modulation of a phosphorylation event, but IKK inhibition might 
play a role. A) EF24 inhibits the IKK kinase in Xenopus extracts. Extracts treated as indicated were analyzed by immunoblot 
using xFANCD2, IκB-α and tubulin-α antibodies. IκB-α protein level was used as readout for monitoring IKK inhibition. B) The 
specific IKK inhibitor compound BMS-345541 (IKK inhibitor III, Calbiochem) inhibits xFANCD2-Ub in extracts. Experiment 
was performed as in (A). The structure of BMS-345541 is shown. The star denotes a non-specific band used as loading control. 
C) EF24-dependent inhibition of xFANCD2-Ub is not affected by co-treatment with tautomycin (phosphatase inhibitor), caf-
feine (kinase inhibitor) and SAP (shrimp alkaline phosphatase). Extracts treated as indicated were analyzed by immunoblot 
using xFANCD2 and xMRE11 antibodies. xMRE11 phosphorylation status was used to monitor the efficiency of tautomycin, 
caffeine and SAP treatments.Page 5 of 13
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absence of ATM.
4H-TTD, a novel curcumin analog with properties similar 
to EF24
We previously identified several small molecule inhibi-
tors of the FA pathway using the Xenopus cell-free assay
[6]. Structural analysis revealed that one of the com-
pounds (E3 of the Challenge Set library, NCI) is a curcu-
min analog that resembles EF24 (Fig. 7A). The structure
incorporates a sulfone moiety instead of an amine in the
central ring and p-nitro substitution in the terminal phe-
nyl rings instead of o-fluoro groups. Its chemical name,
4H-Thiopyran-4-one, tetrahydro-3,5-bis [(4-nitrophe-
nyl)methylene]-,1,1-dioxide, was abbreviated to 4H-TTD
for convenience. Comparison with curcumin and EF24
revealed that 4H-TTD is slightly less active than EF24 for
FA pathway inhibition in Xenopus extracts (IC50: 250 μM
vs. 150 μM, Fig. 7B). In HeLa cells, 4H-TTD inhibited HU-
induced hFANCD2-Ub at sub-micromolar concentra-
tions, similar to EF24 (IC50: 0.12 μM, Fig. 7C). We next
tested 4H-TTD activity in the survival assay described in
the previous paragraph (Fig. 6). Like EF24, 4H-TTD dis-
played more toxicity in 309ATM KO cells, with a 3-fold dif-
ference compared to WT cells (0.18 vs. 0.5 μM, Fig. 7D).
The overall cell toxicity was in the nanomolar range,
about 10 times lower than EF24, suggesting that 4H-TTD
has a general cellular toxicity greater than EF24.
These results underscore the use of Xenopus egg extracts as
a useful screening strategy to rapidly identify inhibitors of
the FA pathway and further validates this class of com-
pounds as potent FA pathway inhibitors and potential
anticancer agents for synthetic lethal relationship-based
targeted therapy.
Discussion
DNA damage response pathways have recently been the
target of considerable efforts in oncology research. This is
due in part to the successful treatment of BRCA-deficient
tumors with PARP1 inhibitors [8,9], which demonstrated
that taking advantage of the synthetic lethal relationship
between two DNA damage genes is a valid approach for
the development of novel targeted therapies in oncology
EF24 inhibits hFANCD2-Ub and foci formation in HeLa cells and is more active than curcuminFigure 4
EF24 inhibits hFANCD2-Ub and foci formation in HeLa cells and is more active than curcumin. A) Hydroxyurea-
induced FANCD2-Ub in HeLa cells is inhibited by EF24 at lower concentrations than curcumin. hFANCD2-Ub was monitored 
by immunoblot and densitometry analysis to determine IC50. B) Hydroxyurea-induced hFANCD2 foci formation is inhibited by 
EF24. hFANCD2 foci were detected by immunofluorescence and the percentage of cells with more than 5 foci was determined 
for each treatment. Histograms represent the average of 3 experiments. Error bars represent standard deviation.Page 6 of 13
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interaction to be exploited therapeutically against cancers:
first, functional deficiency of one of the genes has to be a
causative event of the tumorigenesis. Impairment of DNA
damage responses, which is strongly suspected to be one
of the most common initial event during tumorigenesis
[37], fits this requirement. The second condition is that
the target of the therapeutic agent is not an essential gene,
hence limiting toxicity and increasing the therapeutic win-
dow. Many DNA damage response pathways are partially
redundant, explaining why one defect is usually well tol-
erated at least in the short term, e.g. PARP1 [7,38].
Synthetic lethal interactions between the FA pathway and
other DNA damage response genes such as ATM, PARP1
and NBS1 have been identified recently [12], stimulating
interest in determining if FA pathway inhibitors would
selectively target tumor cells deficient in these genes. For
instance, ATM mutations are highly prevalent (approx.
50%) in mantle cell lymphoma patients [16], raising the
possibility that these tumors might be selectively treated
with a FA pathway inhibitor.
The first identified FA pathway inhibitor was curcumin
[5]. To improve potency and specificity, we compared the
FA pathway inhibition activity of a series of monoketone
analogs of curcumin [18] in Xenopus extracts, and identi-
fied EF24 and 4 other compounds as potent FA pathway
inhibitors. Similar to DDN and other inhibitors we previ-
ously identified [6] and data not shown), curcumin ana-
logs displayed similar activity against MRE11
phosphorylation but did not inhibit RPA32 and H2AX
phosphorylation. This finding will be important practi-
cally for the design of a high-throughput assay, allowing
rapid discrimination between specific FA pathway inhibi-
tors and those that also inhibit MRE11 phosphorylation.
Structure-activity relationships
Structural similarity of EF24 and 4H-TTD confirmed that
monoketone analogs of curcumin form a new class of FA
EF24 sensitizes the HSC 72OT+A cell line to MMC but not its FA-deficient counterpart, HSC 72OTFigure 5
EF24 sensitizes the HSC 72OT+A cell line to MMC but not its FA-deficient counterpart, HSC 72OT. A) Effect of 
the combination of MMC and EF24 treatment on the viability of HSC 72OT and HSC 72OT+A cells. HSC 72OT (patient-
derived FANCA-deficient cell line) and HSC 72OT+A (FANCA-complemented isogenic cell line) were treated with various 
concentrations of MMC only (solid lines) or MMC + 100 nM EF24 (dashed lines). Cell viability was measured after 3 days by 
MTS assay. B) Similar experiment was performed using EF24 only.Page 7 of 13
(page number not for citation purposes)
Molecular Cancer 2009, 8:133 http://www.molecular-cancer.com/content/8/1/133pathway inhibitors. Within the same structural template,
heteroatom ring replacements and a subset of terminal
aromatic ring substituents appear to account for the
potency of a given compound. With respect to the central
six-membered ketone for example, the piperidone deriva-
tives (EF24, EF31, AS153-4, and AS153-5) are much more
potent than the corresponding thio-pyran analog (AS153-
1). However, decorating the nitrogen of the piperidone
with a strong electron withdrawing group that diminishes
the basicity of the nitrogen, for instance the Boc group,
causes complete loss of activity (0616-104). Switching
from piperidone to pyran or cyclohexanone likewise
decreases activity to undetectable levels in Xenopus
extracts (AS153-2 and 0810-117). By contrast, the central
sulfone of 4H-TTD restores activity perhaps by virtue of its
unique ability to serve as a proton acceptor on both faces
of the central ring. With respect to terminal ring substitu-
tion, the moieties that deliver the most potent analogs are
F, OH and the pyridine nitrogen (Fig. 1) [18]. Aromatic
nitro groups coupled with a central ring sulfone as repre-
sented by 4H-TTD (Fig. 7A) represents a novel combina-
tion. This emerging SAR provides a direction for further
optimization. For example, it will be instructive to see if
combining nitro groups with a piperidone ring or fluoro
substituents with sulfone will either match or enhance the
observed activities.
While exploring the mechanism of FA pathway inhibi-
tion, we found that EF24 is a weak proteasome inhibitor.
The more effective proteasome inhibition by curcumin
EF24 but not curcumin or DRB is more toxic to ATM-deficient mouse kidney cells than wild-type cellsFigure 6
EF24 but not curcumin or DRB is more toxic to ATM-deficient mouse kidney cells than wild-type cells. A) 
309ATM KO and 334ATM WT cells were treated with various concentrations of EF24. Cell viability was measured after 3 days by 
MTS assay. Each point represents the mean of 3 repeats. Error bars represent standard deviation. B) Similar experiment was 
performed using curcumin. C) Similar experiment was performed using DRB, a caseine kinase II inhibitor that does not inhibit 
the FA pathway in Xenopus extracts.Page 8 of 13
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monocarbonyl analogs. Three prominent structural ele-
ments that differentiate the two chemical classes are the
central rigidifying ring in the analogs, the presence of the
central three-carbon unit bearing two oxygens and the
phenolic oxygens in curcumin. The antioxidant properties
of curcumin are generally attributed to the radical scav-
enging abilities of the phenolic OH groups [39] and the
central 1,3-diketone functionality [40]. Thus, either radi-
cal scavenging or a change in molecular architecture or
both may be the basis for curcumin's superior activity
against the proteasome. This result implies that EF24 has
a spectrum of activities narrower than curcumin.
Inhibition of the FA pathway in cells
With activity in the nanomolar range in cells, EF24 and
4H-TTD are the most active FA pathway inhibitor identi-
fied so far [5,6,30]. As previously noted [6], EF24 and 4H-
TTD effective concentrations were 2 to 3 orders of magni-
tude lower in cells than in extracts, probably because of
the strong quenching occurring in extracts due to high
proteins and lipids content [41].
We next tested whether inhibition of the FA pathway by
EF24 could be exploited to target cells using sensitization
and synthetic lethal interaction approaches. Using a com-
bination strategy [6], we found that a non-toxic dose of
EF24 sensitized FA-competent cells to the DNA crosslink-
ing agent MMC. EF24 failed to sensitize isogenic FA-defi-
cient cells to MMC, suggesting that inhibition of the FA
pathway rather than pleiotropic activity was responsible
for the sensitization phenotype observed (Fig. 5). Hence
EF24 might be an interesting lead as a chemosensitizer for
DNA crosslinking agents such as MMC and platinium
compounds.
Next, EF24 and 4H-TTD were used as single agents in con-
genic cell lines differing in their ATM status. We found
that both compounds were significantly more toxic to
ATM KO cells than WT cells. These results are consistent
Monoketone analogs of curcumin form a new class of FA pathway inhibitorsFigure 7
Monoketone analogs of curcumin form a new class of FA pathway inhibitors. A) Identification of 4H-TTD in an inde-
pendent screen for FA pathway inhibitors. Each compound of row E of the NCI Challenge Set library plate was tested at 0.5 
mM in Xenopus extracts for inhibition of xFANCD2-ub and xMRE11-P. Arrow indicates the active compound. The chemical 
structure of 4H-TTD is shown. B) Comparison of xFANCD2-Ub inhibition activity of 4H-TTD, EF24 and curcumin in Xenopus 
extracts. xFANCD2-Ub IC50 were determined as in Fig. 1A. C) 4H-TTD inhibits the FA pathway in HeLa cells. IC50 was deter-
mined as in Fig. 4A. D) 4H-TTD is more toxic to 309ATM KO than 334ATM WT cells.Page 9 of 13
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cumin analogs triggered a synthetic lethal effect in ATM-
deficient cells [12]. The failure of curcumin to display the
same effect could be due to the fact that its weak activity
against the FA pathway is masked by the activity toward
numerous other targets, for instance the proteasome.
Mechanism of FA pathway inhibition
EF24 did not inhibit the FA pathway by well-known
mechanisms such as disrupting the integrity of the FA core
complex [42], impairement of recruitment of FA proteins
to DNA substrates [24] or proteasome inhibition [30].
Surprisingly, proteasome inhibition did not affect
xFANCD2-Ub in Xenopus extracts, suggesting that the pro-
teasome is not involved in the basic activation of the FA
pathway. Rather, it may be required in the more complex
cellular environment to overcome the chromatin barrier
or to respond to specific DNA lesions [30]. Importantly,
this finding further highlights the use of the Xenopus
extracts-based screening assay to identify compounds that
are more likely to target the core FA pathway rather than
general regulators. Underscoring this notion, monoubiq-
uitylation of FANCD2 is also independent of phosphor-
ylation in DNA-stimulated extracts (Fig. 3C[24]).
Interestingly, Aleo E. et al [43] identified 4H-TTD (called
"G5" in their work) in a screen for compounds that trigger
caspase activation in a BCL-2 dependent and caspase 9-
independent manner. 4H-TTD did not inhibit proteas-
ome activity, confirming the data obtained with EF24 and
related analogs. Instead, 4H-TTD exhibited ubiquitin iso-
peptidase/deubiquitinase (DUB) inhibition activity.
Structural analysis further revealed a molecular determi-
nant shared with known ubiquitin isopeptidase inhibitors
[43] that is also present in EF24, raising the possibility
that monoketone analogs of curcumin could inhibit
FANCD2- Ub through a novel mechanism involving DUB
inhibition independently of the proteasome.
During this study, we found that EF24 inhibits the phos-
phorylation of xMRE11 and xFANCM in Xenopus extracts
(Fig. 1, 3 and Additional File 1 - Fig S1). Since both pro-
teins are the target of the DNA damage signaling and
checkpoint kinases ATM and ATR [28,44], we tested
whether EF24 treatment affected the phosphorylation sta-
tus of a classic ATR target, CHK1 [45]. Reprobing the EF24
blot shown in Fig. 7B with a phospho-CHK1-specific anti-
body revealed that CHK1-P was inhibited at the highest
EF24 concentration tested (400 mM, Additional File 1 -
Summary of the mechanistic findings presented in this paperFigure 8
Summary of the mechanistic findings presented in this paper. The ATM and FA pathways (white boxes/arrows) are 
two DNA damage response pathways that display synthetic lethal relationship. Inhibition of the FA pathway may therefore be 
used as a targeted therapy to selectively kill ATM-deficient tumors. Several enzymatic complexes have been proposed to mod-
ulate the FA pathway (light grey boxes). Monitoring the effect of the compounds used in this study (dark grey boxes) toward 
those enzymatic activities suggests that (i) in contrast with cell-based assays, the proteasome is not required for FA pathway 
activation in Xenopus extracts, (ii) in contrast with curcumin, EF24 is a weak proteasome inhibitor, (iii) EF24 does not inhibit 
the FA pathway through disruption of the core complex, and (iv) curcumin, EF24 and BMS-345541 might inhibit the FA path-
way through inhibition of IKK.Page 10 of 13
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fide but weak ATR inhibitor. Since FANCD2 monoubiq-
uitylation has been shown to be dependent on ATR both
in mammalian cells [46,47] and in replicating Xenopus
extracts [23,26,44], it was therefore tempting to hypothe-
size that EF24 inhibits FANCD2-Ub through ATR inhibi-
tion. However our lab has clearly demonstrated that
FANCD2-Ub is not dependent on ATR in non-replicating,
DNA substrate-stimulated extracts: chemical inhibition of
ATR by caffeine or depletion of ATR and its essential part-
ner ATRIP have no detectable effect on FANCD2-Ub in
this setting (Fig. 3C and [24,44]). Taken together, these
data suggest that EF24 might be a weak ATR inhibitor, but
this activity does not account for FANCD2-Ub inhibition
in non-replicating extracts.
An alternative hypothesis emerged from the fact that one
of the cellular targets of curcumin and EF24 is the IκB
kinase complex (IKK), a major component of the NF-κB
pathway. Otsuki et al [33] showed that IKK interacts with
the FA core complex, raising the possibility that EF24
might inhibit the FA pathway by targeting IKK. This
hypothesis is in line with the fact that curcumin has a
weaker inhibitory activity than EF24 toward both IKK and
xFANCD2-Ub (Fig. 1, Fig. 4 and [32]). Interestingly, we
found that the specific IKK inhibitor BMS-345541 [34]
inhibited xFANCD2-Ub in a manner similar to EF24, i.e.
xFANCD2-Ub inhibition occurred at higher concentra-
tion than IkB-α stabilization (Fig 3A, B). This differential
effect is reminiscent of the fact that BMS-345541 is 10-
fold more active on IKK-2 (IKKβ) than on IKK-1 (IKKα),
maybe because allosteric binding induces a different con-
formational change in the two IKK subunits [34]. The lat-
ter result also suggests that the kinase activity of IKK is not
required for plasmid activation of the FA pathway in
extracts. The fact that general phosphorylation modula-
tors did not interfere with EF24 (Fig. 3C) provided an
indirect confirmation of this hypothesis. Additional
experiments are needed to explore the potential link
between EF24, IKK and the FA pathway.
Like curcumin, the mimics depicted in Figure 1 are pleio-
tropic agents with activities as diverse as mitochondrial
redox-mediators [19], tubulin dynamics disrupters [22],
kinase inhibitors [32], glioma cell radiosensitizers [48]
and angiogenesis blockers [21]. Although their multiplic-
ity of actions is complex, predictive pharmacological
models [49] and optimization [50] are emerging within
systems biology. The discovery that monoketone analogs
of curcumin form a new class of FA pathway inhibitors
not only underscores their potential for low toxicity tar-
geted cancer therapy, it also adds to the still incomplete
network of beneficial biological actions exerted by these
multi-tasking agents.
Conclusions
Using curcumin as a lead we identified EF24, a monoke-
tone analog with improved activity and specificity toward
the FA pathway. An independent screen identified 4H-
TTD, a structurally related compound with similar activi-
ties, suggesting that monoketone analogs form a new class
of FA pathway inhibitors. Fig. 8 summarizes the main
mechanistic findings of the study.
To our knowledge, this is the first report suggesting that
small molecule inhibition of the FA pathway may specifi-
cally target ATM-deficient cells. Additional experiments
are under way to confirm this synthetic lethal effect and to
test whether these compounds are effective in human
ATM-deficient cancer cells as well.
Methods
Chemicals and antibodies
Monoketone analogs of curcumin were prepared as previ-
ously described [18]. Pure curcumin, MG132 (Calbio-
chem), IKK inhibitor III (BMS-345541, Calbiochem),
DRB (Calbiochem), 4H-TTD (NSC 144303, NCI/DTP
Open Chemical Repository, http://dtp.nci.nih.gov) were
resuspended in DMSO, tautomycin (Calbiochem) in
EtOH, caffeine and hydroxyurea (Sigma) in H2O. Shrimp
alkaline phosphatase was from Fermentas. Antibodies
against xFANCD2, xFANCG, xFANCA and hFANCD2
were described previously [6]. Antibodies against γH2AX
and IkB-α were from Bethyl laboratories (#A300-081A)
and cell Signaling (#9242), respectively. Antibodies
against xRPA, xMre11 and hFANCD2 (for immunofluo-
rescence) were kind gifts of K. Cimprich, J. Gautier and
K.J. Patel, respectively.
Xenopus cell-free assay and immunoblotting
Preparation of Xenopus laevis low-speed extracts and the
FA pathway assay were described previously [6].
Proteasome assay
Fluorogenic peptides (Proteasome Substrate Pack
#PW9905) specific for the chymotrypsin-like and caspase-
like activities of the proteasome were incubated in Xenopus
extracts treated with serial dilutions of various com-
pounds. Fluorescence emitted by proteasome cleavage of
the peptides was monitored using a fluorometer (FluoStar
Galaxy, BMG Labtech) with 380 nm and 460 nm excita-
tion and emission filters, respectively. Experiments were
repeated at least twice. Due to the large variability of activ-
ity between extract batches, one representative experiment
is shown.
Cell lines and cell culture
HeLa cells were grown in DMEM medium supplemented
with 10% serum in humidified 5% CO2 atmosphere.
ATM-deficient and ATM-proficient kidney cells from con-Page 11 of 13
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grown in the same medium.
hFANCD2 ubiquitylation assay and immunofluorescence 
microscopy in HeLa cells
hFANCD2 ubiquitylation assay and immunofluorescence
assays in HeLa cells have been described elsewhere [6].
Survival assays
HSC72OT and HSC72OT+A cells were seeded at 5,000
per well in 96-well plates, and treated 24 hrs later with var-
ious concentrations of compounds or DMSO (1 μl in 100
μl medium). 309ATM KO and 334ATM WT cells were seeded at
7,000 per well and treated immediately. Cell survival was
measured after 3 days using the CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega) following the
recommendations from the manufacturer. All experi-
ments were done in triplicate.
Calculation of IC50 values
Fitted curves were determined from experimental data
using IgorPro. The concentration of compound that
induces 50% inhibition of the measured endpoint (i.e.
FANCD2 ubiquitylation, Mre11 phosphorylation and cell
survival) was then plotted on the fitted curve.
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